Skip to main content
SpringerLink
Log in

Serological lymphocytic activity and patient-reported outcomes in Sjögren’s syndrome

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study was set to investigate whether serum markers of lymphocytic activity are associated with patient-reported outcomes in Sjögren’s syndrome (SS). Forty-six patients with SS were included in this cross-sectional study. Patients with monoclonal gammopathy, history of malignant lymphoma, or with secondary SS were excluded. Serum levels of IgG, β2-microglobulin (β2M), soluble interleukin-2 receptor (sIL2-R), and free light chains (FLC) were assessed. Systemic disease activity was measured by the EULAR SS disease activity index (ESSDAI). Patient-reported symptoms were recorded by visual analogue scales (VAS) of pain, fatigue, and dryness, as compiled in the EULAR SS patient-reported index (ESSPRI). Depressive symptoms were determined by the Patient Health Questionnaire 9 (PHQ-9). Serum concentrations of κFLC (r = 0.491, p = 0.001), λFLC (r = 0.326, p = 0.027), and β2M (r = 0.421, p = 0.004) correlated with the ESSDAI, whereas sIL-2R and IgG did not. No correlations between serum markers of lymphocytic activity and the ESSPRI, or single VAS measures of pain, dryness, or fatigue, were found. In patients with VAS fatigue scores in the upper quartile, sIL-2R serum levels were even decreased (p = 0.019). Only depressive symptoms as determined by PHQ-9 were positively correlated with fatigue (r = 0.536, p < 0.001). In this well-defined cohort of patients with SS, serological lymphocytic activity was not correlated with patient-reported outcomes and sIL-2R levels were even decreased in patients with high fatigue scores. Only depressive symptoms were correlated with fatigue. This highlights the need to further understand the link between inflammation and disease characteristics in SS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331

    Article  PubMed  CAS  Google Scholar 

  2. Pertovaara M, Korpela M (2011) Serum β2 microglobulin correlates with the new ESSDAI in patients with Sjögren’s syndrome. Ann Rheum Dis 70:2236–2237

    Article  PubMed  CAS  Google Scholar 

  3. Gottenberg J, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P et al (2013) Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren’s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 8:e59868

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Spadaro A, Riccieri V, Benfari G, Scillone M, Taccari E (2001) Soluble interleukin-2 receptor in Sjögren’s syndrome: relation to main serum immunological and immunohistochemical parameters. Clin Rheumatol 20:319–323

    Article  PubMed  CAS  Google Scholar 

  5. Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Yves Hatron P, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Saliou P, Pers JO, Seror R, Saraux A (2017) Severe health-related quality of life impairment in active primary Sjögren’s syndrome and patient-reported outcomes: data from a large therapeutic trial. Arthritis Care Res (Hoboken) 69:528–535

    Article  Google Scholar 

  6. Ng WF, Bowman SJ (2010) Primary Sjögren’s syndrome: too dry and too tired. Rheumatology (Oxford) 49:844–853. https://doi.org/10.1093/rheumatology/keq009

    Article  Google Scholar 

  7. Hart BL (1988) Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12:123–137

    Article  PubMed  CAS  Google Scholar 

  8. Howard Tripp N, Tarn J, Natasari A, on behalf of the United Kingdom Primary Sjögren’s Syndrome Registry et al (2016) Fatigue in primary Sjögren’s syndrome is associated with lower levels of proinflammatory cytokines. RMD Open 2:e000282. https://doi.org/10.1136/rmdopen-2016-000282

    Article  PubMed  PubMed Central  Google Scholar 

  9. Bax HI, Vriesendorp TM, Kallenberg CGM, Kalk WW (2002) Fatigue and immune activity in Sjögren’s syndrome. Ann Rheum Dis 61:284

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E, Brun JG, Kruize AA, Praprotnik S, Tomsic M, Gottenberg JE, Devauchelle V, Devita S, Vollenweider C, Mandl T, Tzioufas A, Carsons S, Saraux A, Sutcliffe N, Vitali C, Bowman SJ, Sjögren's Task Force EULAR (2011) EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis 70:968–972

    Article  PubMed  Google Scholar 

  11. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61:554–558

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C, Sjögren's Task Force EULAR (2010) EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 69:1103–1109

    Article  PubMed  Google Scholar 

  13. Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606–613

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172–3177

    PubMed  CAS  Google Scholar 

  15. Pratt G (2008) The evolving use of serum free light chain assays in haematology. Br J Haematol 141:413–422. https://doi.org/10.1111/j.1365-2141.2008.07079.x

    Article  PubMed  CAS  Google Scholar 

  16. Karlsson FA, Wibell L, Evrin PE (1980) Beta 2-Microglobulin in clinical medicine. Scand J Clin Lab Invest Suppl 154:27–37

    PubMed  CAS  Google Scholar 

  17. Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, Sivils K, Theander E, Tzioufas A, Ramos-Casals M (2016) Sjögren syndrome. Nat Rev Dis Primers 2:16047. https://doi.org/10.1038/nrdp.2016.47. Review.

  18. Harboe E, Tjensvoll AB, Vefring HK, Gøransson LG, Kvaløy JT, Omdal R (2009) Fatigue in primary Sjögren’s syndrome—a link to sickness behaviour in animals? Brain Behav Immun 23:1104–1108

    Article  PubMed  CAS  Google Scholar 

  19. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot J, Perdriger A, Puéchal X et al (2014) Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 160:233–242. https://doi.org/10.7326/M13-1085

    Article  PubMed  Google Scholar 

  20. Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, Desmoulins F, Nocturne G, Ravaud P, de Vita S (2015) Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 74:526–531

    Article  PubMed  CAS  Google Scholar 

  21. Gottenberg J, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost J, Rist S, Saraux A, Devauchelle-Pensec V, Morel J, Hayem G, Hatron P, Perdriger A, Sene D, Zarnitsky C, Batouche D, Furlan V, Benessiano J, Perrodeau E, Seror R, Mariette X (2014) Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 312:249–258. https://doi.org/10.1001/jama.2014.7682

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank the patients who contributed to this study.

Author information

Authors and Affiliations

  1. Department of Rheumatology and Clinical Immunology, Medical Centre – University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany

    Maike Jülich, Anna-Maria Kanne, Bettina Sehnert & Reinhard E. Voll

  2. Department of Pneumology, Rheumatology, and Nephrology, RoMed Medical Centre, Pettenkoferstr. 10, 83022, Rosenheim, Germany

    Stephan Budweiser

  3. Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Freiburgerstrasse 10, 3010, Bern, Switzerland

    Florian Kollert

Authors
  1. Maike Jülich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna-Maria Kanne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bettina Sehnert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephan Budweiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reinhard E. Voll
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Florian Kollert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Kollert.

Ethics declarations

Ethical standards

This study has been approved by the ethics committee of the University of Freiburg and was conducted in compliance with the Declaration of Helsinki and its later amendments. All patients gave their informed consent prior to inclusion in the study.

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jülich, M., Kanne, AM., Sehnert, B. et al. Serological lymphocytic activity and patient-reported outcomes in Sjögren’s syndrome. Clin Rheumatol 37, 2361–2366 (2018). https://doi.org/10.1007/s10067-018-4159-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4159-2

Keywords

Search

Navigation